Novartis AG has announced positive results from the APPULSE-PNH Phase IIIB study, which evaluated the efficacy and safety of the oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). The study focused on patients with hemoglobin levels of at least 10g/dL who switched from anti-C5 therapies. After 24 weeks of treatment, patients experienced an average hemoglobin level improvement of 2.01 g/dL, with most achieving normal or near-normal levels. Additionally, patients reported improvements in fatigue and maintained control over both intravascular and extravascular hemolysis. No new safety signals were observed. These findings will be presented at the European Hematology Association Congress 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。